US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium
Categories: Breast Cancer
THE WOODLANDS, Texas, Dec. 14 /PRNewswire/ — Seven leading cancer physicians and investigators affiliated with US Oncology Research participated in studies that were presented orally at the 2009 San Antonio Breast Cancer Symposium, held Dec. 9-13 at the Henry B. Gonzalez Convention Center in San Antonio, Texas. Fifteen others presented their research in poster presentations during the conference.
Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, and Lina Asmar, Ph.D., director of Biostatistics and Medical Writing at US Oncology, were co-authors on a team that presented results at 9:15 a.m. on Thursday, Dec. 10, regarding the five-year analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. The study was titled “Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer.”
“The TEAM trial is the largest aromatase inhibitor study ever to be conducted. The overall results are positive with an improvement in outcome measured by several parameters and a favorable safety profile for exemestane relative to a worldwide standard, tamoxifen,” said Dr. Jones. “This very large study is a treasure trove of substudies, providing valuable scientific information for women with breast cancer.”
Dr. Jones was also an investigator in Thursday’s 9:30 a.m. oral presentation, titled, “Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES)” and several poster sessions listed below. Dr. Asmar also co-authored many of the poster presentations listed below.
Nicholas Robert, M.D., investigator at Fairfax-Northern Virginia Hematology-Oncology, an affiliate of US Oncology, participated in three oral presentations at the symposium: